<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04464577</url>
  </required_header>
  <id_info>
    <org_study_id>CV018-014</org_study_id>
    <nct_id>NCT04464577</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235</brief_title>
  <official_title>A Phase 1, Open-label Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Pharmacokinetics and Safety of BMS-986235</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of inhibitors, at steady state, on the drug levels,
      safety, and tolerability of BMS-986235 when taken by healthy participants. The inhibitors to
      be utilized in this study are fluconazole, bupropion, and itraconazole.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">June 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration (AUC(0-T)) of BMS-986235 with fluconazole</measure>
    <time_frame>Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of BMS-986235 with fluconazole</measure>
    <time_frame>Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC(INF)) of BMS-986235 with fluconazole</measure>
    <time_frame>Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC(INF)) of BMS-986235 with bupropion</measure>
    <time_frame>Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration (AUC(0-T)) of BMS-986235 with bupropion</measure>
    <time_frame>Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of BMS-986235 with bupropion</measure>
    <time_frame>Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration (AUC(0-T)) of BMS-986235 with itraconazole</measure>
    <time_frame>Day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC(INF)) of BMS-986235 with itraconazole</measure>
    <time_frame>Day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of BMS-986235 with itraconazole</measure>
    <time_frame>Day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC(INF)) of BMS-986235</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration (AUC(0-T)) of BMS-986235</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of BMS-986235</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Nonserious Adverse Events (AEs)</measure>
    <time_frame>Up to 49 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes from baseline in vital signs: Body Temperature</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes from baseline in physical examinations</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in clinical laboratory tests: Hematology</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in clinical laboratory tests: Clinical Chemistry</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in clinical laboratory tests: Coagulation</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in clinical laboratory tests: Urinalysis</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes from baseline in vital signs: Respiratory Rate</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes from baseline in vital signs: Heart Rate</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes from baseline in vital signs:Blood Pressure</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in electrocardiogram (ECG)</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in vital signs: Oxygen saturation (the amount of oxygen in blood (SpO2))</measure>
    <time_frame>Up to 44 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Arm A: BMS-986235+Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: BMS-986235+ Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: BMS-986235+ Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Arm A: BMS-986235+Fluconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Arm B: BMS-986235+ Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Arm C: BMS-986235+ Itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986235</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Arm A: BMS-986235+Fluconazole</arm_group_label>
    <arm_group_label>Arm B: BMS-986235+ Bupropion</arm_group_label>
    <arm_group_label>Arm C: BMS-986235+ Itraconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Body mass index of 18.0 kg/m2 to 32.0 kg/m2, inclusive, at screening.

          -  Males and females must agree to follow specific methods of contraception, if
             applicable.

          -  Healthy participants, as determined by no clinically significant deviation from normal
             in physical examination, ECGs, and clinical laboratory determinations, and no
             significant findings in medical history.

        Exclusion Criteria:

          -  Women of childbearing potential (WOCBP), women who are pregnant or breastfeeding

          -  Inability to tolerate oral medication

          -  Known previous exposure to BMS-986235.

        Other protocol-defined inclusion/exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences - Salt Lake</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

